Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Postmarket

Last Trade
Delayed
$143.95
0.08 (0.06%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$143.87
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
144.77
Day's Low
143.61
Volume
(Heavy Day)
Volume:
11,036,045

10-day average volume:
7,026,433
11,036,045

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

8:00 pm ET October 15, 2020 (Globe Newswire) Print

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation concerns whether Eli Lilly has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On August 2020, Eli Lilly began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.

On October 13, 2020, the trial's sponsor, the National Institute of Allergy and Infectious Diseases ("NIAID") recommended that the trial be paused after an analysis of safety data found "an overall difference in clinical status between the group receiving LY-CoV555 and the group receiving saline placebo."

On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.

The same day, after the market closed, Reuters reported that U.S. Food and Drug Administration ("FDA") inspectors "uncovered serious quality control problems" at Eli Lilly's pharmaceutical plant that will manufacture COVID-19 drugs, including its antibody therapy. The article further stated: "Following its November inspection, the FDA classified the problems as the most serious level of violation, resulting in an 'Official Action Indicated' (OAI) notice." Among other things, the FDA "found that data on the plant's various manufacturing processes had been deleted and not properly audited."

If you purchased or otherwise acquired Eli Lilly shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.